ODH Hip System
DeviceOther names: Total Hip Replacement, THR, Total Hip Arthroplasty, THA
NCT Number: NCT02154516
The purpose of this study is to assess the early and long term safety and efficacy of the hard-on-hard total hip replacement system (R3 ODH-ODH utilization) in patients with non-inflammatory arthritis.
Looking for future studies?
Notify Me21 year and older
All sexes
Interventional
Not applicable
Entabeni Hospital, Durban, South Africa
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
10 year extension:
Exclusion criteria
10 year extension:
Other names: Total Hip Replacement, THR, Total Hip Arthroplasty, THA
Time frame: Postoperatively through 10 years
Device related revisions reported by the number of participants with a revision required (Yes/No).
Time frame: 3 months, 6 months, 1 year, 2 years, 5 years, 7 years and 10 years post-operatively.
For both investigational (i.e., Investigational Hard-on-Hard Total Hip Replacement Device) and control (i.e., Control Total Hip Replacement Device) participants, metal ion concentration in whole blood were measured for Cobalt (Co), Chromium (Cr), Nickel (Ni), Titanium (Ti), Zirconium (Zr), Niobium (Nb), Molybdenum (Mo), Vanadium (V) and Aluminum (Al) at each indicated time frame.
Time frame: Preoperatively, 3 months, 6 months, 1 year, 2 years, 5 years, 7 years and 10 years post-operatively.
The Harris Hip Score (HHS), which ranges from 0 (worst) to 100 (best), considers information on pain, function, and range of motion. HHS was measured for Investigational Hard-on-Hard Total Hip Replacement Device only.
Time frame: Preoperatively, 3 months, 6 months, 1 year, 2 years, 5 years, 7 years, 10 years
The Hip Disability and Osteoarthritis Outcome Scores (HOOS) was measured for Investigational Hard-on-Hard Total Hip Replacement Device only and included 40 items with five responses from five subcategories of Pain, Symptoms and Stiffness, Activities of Daily Living, Function in Sports and Recreational Activities, and Quality of Life to produce a total HOOS. The total HOOS scale ranged from 0 to 100, with 0 indicating the worst possible score and 100 indicating the best possible score.
Time frame: 3 months, 6 months, 1 year, 2 years, 5 years, 7 years and 10 years post-operative
Radiolucencies determined by number of participants with occurrence of radiolucent lines and osteolysis (Yes/No)
Time frame: 3 months, 6 months, 1 year, 2 years, 5 years, 7 years and 10 years post-operative
Occurrence of Heterotopic Ossification in participants (Yes/No)
Time frame: 3 months, 6 months, 1 year, 2 years, 5 years, 7 years and 10 years post-operative
Occurrence of Subsidence in Investigational Hard-on-Hard Total Hip Replacement Device participants (Yes/No) categorized by:
Time frame: Intra-operative, up to 50 minutes
Blood loss during surgery measured in milliliters (ml) of blood
Time frame: Hospital admission to discharge
Length of stay measured by number of days spent in hospital
Time frame: Intra-operative
Operative time in minutes from first incision into skin to time when last suture is applied for the Investigational Hard-on-Hard Total Hip Replacement Device group only
Time frame: Up to 10 years
Re-hospitalizations measured by the number of re-admissions to hospital
Smith & Nephew, Inc.
Industry
A Consecutive Series Pilot Study Evaluating the Safety and Effectiveness of a New Hard-on-Hard Total Hip Replacement System in Patients With Non-inflammatory Arthritis With a Standard THA Metal Ion Control Group
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06080412
Arthritis, Arthritis Shoulder
Boulogne-Billancourt, France
View Trial DetailsNCT02967874
Arthritis, Arthritis, Degenerative
Novosibirsk, Russia
View Trial DetailsNCT03142178
Arthritis, Arthritis, Degenerative
Columbus, Ohio, United States
View Trial DetailsNCT02784626
Arthritis, Arthritis, Degenerative
Seongnam-si, Gyeonggi-do, South Korea
View Trial Details